Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
Dare Bioscience Inc (NASDAQ: DARE) is a clinical-stage biopharmaceutical leader advancing innovative therapies for women’s reproductive and sexual health. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical trial progress, regulatory milestones, and strategic partnerships.
Track the latest developments across DARE’s pipeline of non-hormonal contraceptives, sexual health treatments, and cervical health solutions. Our curated news collection includes updates on FDA submissions, trial results for candidates like Ovaprene® and Sildenafil Cream 3.6%, and collaborations advancing women’s healthcare innovation.
Key focus areas include progress toward addressing unmet needs in bacterial vaginosis treatment, female sexual arousal disorder (FSAD), and HPV-related cervical conditions. Bookmark this page for real-time access to earnings announcements, research publications, and licensing agreements that shape DARE’s position in the biopharma sector.
Daré Bioscience, Inc. (NASDAQ: DARE) announced positive topline results from its Phase 1/2 clinical study of DARE-VVA1, a novel intravaginal formulation for treating vulvar and vaginal atrophy (VVA) in postmenopausal women, particularly those with hormone receptor-positive breast cancer. The study demonstrated safety and tolerability, with significant improvements in vaginal cytology and bothersome symptoms. DARE-VVA1 could become the first FDA-approved product for VVA in this patient group, addressing a critical unmet need. The study involved 17 participants, with positive outcomes reported across various doses.
Daré Bioscience reported a strong financial position as of September 30, 2022, with $40.4 million in cash. The company received $18 million in non-dilutive cash, bolstering its balance sheet. Key developments include FDA approval for Ovaprene's pivotal study and positive efficacy data for DARE-HRT1. Additionally, subject screening for Sildenafil Cream's Phase 2b RESPOND study has been completed, targeting topline data announcement in Q2 2023. Daré anticipates the first commercial sale of XACIATO in the U.S. in 1H 2023, aimed at addressing bacterial vaginosis affecting 21 million women.
Daré Bioscience, a leader in women’s health innovation, will have its President and CEO, Sabrina Martucci Johnson, present at the Stifel 2022 Healthcare Conference on November 15, 2022, at 9:10 a.m. ET. The presentation will be available via live webcast on the company's website and archived until November 29, 2022. Daré is committed to advancing innovative therapies for women’s health, including FDA-approved products like XACIATO and candidates such as Ovaprene and Sildenafil Cream. For more details, visit their investor relations page.
Daré Bioscience (NASDAQ: DARE) will host a conference call on November 10, 2022, at 4:30 p.m. ET to discuss its Q3 2022 financial results and provide company updates. Interested participants can access the call by dialing (800) 715-9871 for U.S. callers or (646) 307-1963 internationally. The call will also be available via a live webcast on Daré's Investor Relations website. The company focuses on women's health innovations, including its first FDA-approved product, XACIATO, for bacterial vaginosis, and several candidates in clinical development.
Daré Bioscience (NASDAQ:DARE) has completed subject screening for its Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6%, a potential treatment for female sexual arousal disorder (FSAD). Approximately 100 out of the expected 160-170 subjects have completed study assessments to date. Topline data is anticipated by 2Q-2023. This study represents a significant milestone as there are currently no FDA-approved therapies for FSAD, and Sildenafil Cream aims to be the first approved treatment for this condition.
Daré Bioscience announced positive topline results from its Phase 1/2 clinical trial of DARE-HRT1, an investigational intravaginal ring designed to deliver continuous hormone therapy for menopausal symptoms. DARE-HRT1 showed statistically significant improvements in vasomotor symptoms and vaginal conditions associated with menopause, with 100% of participants finding it comfortable to use. The innovative IVR technology allows consistent drug release without a membrane. Daré plans to leverage this data for FDA approval through the 505(b)(2) pathway.
Daré Bioscience (NASDAQ: DARE) has received FDA approval for an Investigational Device Exemption (IDE) to initiate a pivotal study for Ovaprene, a hormone-free monthly contraceptive. The single-arm study will assess Ovaprene's efficacy, safety, and usability. Previous trials indicated Ovaprene effectively blocked sperm entry. The FDA's approval validates the company's data and aligns on study duration and design. If successful, this could lead to marketing approval for what may become the first FDA-approved monthly self-administered contraceptive. Study recruitment is targeted for mid-2023.
Daré Bioscience (NASDAQ: DARE) announced CEO Sabrina Martucci Johnson's participation in two upcoming conferences focused on women’s health. The Informa Connect Women’s Healthcare Access & Innovation Digital Conference will take place on September 21, 2022, featuring a presentation on non-hormonal female contraception. The Longwood Healthcare Leaders Fall Webconference is scheduled for September 22, 2022, and will include a panel on innovative partnerships. Daré aims to advance products that enhance women's health.
Daré Bioscience (NASDAQ: DARE) announced that its President and CEO, Sabrina Martucci Johnson, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference. The event is scheduled from September 12-14, 2022 at the Lotte New York Palace Hotel, with virtual attendance options available.
The chat will start on September 12 at 11:30 AM ET, and can be accessed on-demand through their website until September 26, 2022. Daré is focused on advancing women's health innovations.
Daré Bioscience (NASDAQ: DARE) announced key updates regarding their Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6%, targeting female sexual arousal disorder (FSAD). Enrollment is expected to complete by 4Q-2022, with topline data anticipated in 2Q-2023. This study aims to evaluate the efficacy and safety of the cream compared to a placebo in premenopausal patients. If successful, it could become the first FDA-approved treatment for FSAD, filling a significant market gap as currently no such options exist for women.
FAQ
What is the current stock price of Dare Bioscience (DARE)?
What is the market cap of Dare Bioscience (DARE)?
